Researchers at the University of California San Diego and the Rady Children’s Institute for Genomic Medicine have successfully treated two children with SCN2A-related developmental epileptic encephalopathy (DEE) using personalized, allele-selective antisense oligonucleotides (ASOs). According to a study published July 21, 2026, in Nature Medicine, the therapy reduced seizure frequency by up to 90%, improved developmental milestones, and allowed patients to reduce their reliance on traditional anti-seizure medications.
Targeting SCN2A Mutations at the Genetic Source
SCN2A-related DEE is a rare, severe form of childhood epilepsy frequently linked to monogenic autism. The condition stems from single mutations in the SCN2A gene, which regulates the flow of sodium ions into neurons. These spontaneous, or de novo, mutations trigger abnormal brain excitability, leading to seizures, movement disorders, and gastrointestinal issues. Traditional medications often fail to address this root genetic cause, leaving many families without effective options.
To address this, investigators developed synthetic DNA pieces called allele-selective ASOs. These molecules are engineered to bind to harmless DNA regions adjacent to a child’s specific mutation. By injecting these ASOs into the spinal fluid, clinicians can selectively silence the mutant copy of the gene while allowing the healthy copy to function. Dr. Olivia Kim-McManus, the study’s principal investigator, notes that the therapy is deliberately designed to match an individual’s unique genetic diagnosis, modifying gene expression and protein output.
Did you know?
Unlike permanent gene editing, ASOs do not alter the underlying genetic code. Because the effects are temporary, the therapy must be administered at regular intervals, typically every two to three months.
Clinical Results: Seizure Reduction and Developmental Gains
In two separate n-of-1 clinical trials, researchers monitored a nine-year-old and a 14-year-old over a two-year period. The results, detailed in Nature Medicine, demonstrated significant health improvements across several metrics:
- Seizure Frequency: The nine-year-old patient saw a 26% reduction in daily seizures, while the 14-year-old experienced a 90% drop, achieving periods of seizure-free days.
- Medication Load: Both participants decreased or discontinued certain anti-seizure drugs.
- Developmental Progress: Patients showed improvements in motor skills, language, and adaptive behaviors. Notably, the 14-year-old patient achieved independent walking at age 15.
- Secondary Health: The older patient experienced a reduction in chronic gastrointestinal issues, requiring less medication to manage symptoms.
Safety data remained positive throughout the trial. No serious side effects or ASO-related adverse events were reported, and routine diagnostic tests, including EEGs and ECGs, remained stable.
Scaling Precision Medicine for Rare Diseases
The success of these trials suggests a potential roadmap for treating other neurological conditions caused by single-gene mutations. Dr. Kim-McManus emphasizes that while the therapy is still investigational, the ability to tailor treatment to an individual’s genetic profile marks a shift in how medicine approaches rare diseases. The team even adjusted dosing frequencies for the older patient after observing that his motor improvements began to wane before his next scheduled dose, a move that successfully restored his ability to walk independently.
This “one-off” trial model is now attracting attention from the biotech and pharmaceutical industries. By proving both the safety and efficacy of personalized ASOs, researchers are laying the groundwork to scale these treatments from individual cases to broader groups of patients who share similar genetic backgrounds.
Frequently Asked Questions
How is the SCN2A gene therapy administered?
The therapy is administered via injection into the spinal fluid under anesthesia. It is repeated every two to three months to maintain its therapeutic effect.
Is this a permanent genetic cure?
No. The therapy uses ASOs to modify gene expression rather than permanently editing the DNA. As a result, the treatment must be ongoing to remain effective.
Are there significant side effects?
In the two-year study published in Nature Medicine, researchers reported no serious side effects or ASO-related adverse events in the two participants.
Have questions about how genomic medicine is changing patient care? Join the conversation in the comments below or subscribe to our medical research newsletter for the latest updates on breakthroughs in precision therapy.
Keep reading